Hematological Malignancies In the News
What's it like to work at the center of a true medical and scientific revolution? It's emotional, often overwhelming. But it’s also a place to witness miracles. Such is the life of the clinical research nurses who staff City of Hope's CAR T cell program.
Meet float rider Cheryl Wiers, a wife and mother of two who battled cancer twice only to have it return. She eventually found prolonged remission thanks to a CAR T Cell therapy offered at City of Hope.
Meet City of Hope 2019 Rose Parade float rider Olivia Gaines, an aspiring songwriter and amateur pianist who has witnessed how music speaks to the heart and calms spirits.
City of Hope clinical and laboratory investigators presented leading-edge research, including new targets in CAR T cell therapy, at the 60th annual ASH meeting in San Diego.
Seven City of Hope patients will welcome the New Year atop City of Hope’s 47th Rose Parade float, “Harmony of Hope.” Meet float rider Abraham Laboriel, a world-renowned bassist whose work has been featured in 4,000 recordings and film soundtracks, including “Coco,” “Frozen” and “Incredibles 2.”
Xiuli Wang, Ph.D., research professor at City of Hope, presented encouraging research on using CAR T cell therapy for central nervous system lymphoma at this year's American Society of Hematology conference.
Physicians and researchers at the 2018 American Society of Hematology conference presented clinical trials for new leukemia and lymphoma treatments, laying the groundwork for innovative therapeutic approaches aimed at improving treatment options and quality of life for patients.
City of Hope physicians and researchers at the American Society of Hematology (ASH) meeting in San Diego presented clinical trials for novel leukemia and lymphoma treatments that could improve outcomes for patients.
Leslie Popplewell, M.D., discusses a recent NBC News report that highlighted the small but apparently growing risk of a rare kind of lymphoma in women who have received breast implants.
CAR T cell therapy is one of the most promising new approaches for treating cancer today. Come spend a day learning more about CAR T cell therapy from City of Hope’s resident experts to better understand what is now at the forefront of oncology treatment.
City of Hope announced today that it will present data on new findings on immunotherapies, including CAR T cell therapy, bone marrow transplants and other treatments for blood cancers, at the American Society of Hematology (ASH) Annual Meeting Dec. 1-4 in San Diego.
Now celebrating its 10th year, the Caltech and City of Hope Biomedical Research Initiative continues to change the future of science and medicine.
City of Hope, TGen announce letter of intent to build cell therapy manufacturing facility in Phoenix. The move would enable the organizations to meet a demand for clinical cell therapies that is expected to grow 42 percent annually over the next decade.
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. The immunotherapy trial is the first to deliver CAR T cells directly to the brain of HER2-positive breast cancer patients with brain metastases.
Harnessing the power of CAR T cells
The California Institute for Regenerative Medicine today awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop CAR T cells that can target and kill HIV-infected cells. The treatment will also use the cytomegalovirus vaccine to stimulate the immune system to proliferate and maintain the CAR T cells.
The California Institute for Regenerative Medicine has awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop chimeric antigen receptor (CAR) T cells that can target and kill HIV-infected cells.
Before her bone marrow transplant at City of Hope, Cierra Jackson's future was uncertain thanks to her sickle cell disease. Now, she's pushing forward with her dreams and helping others with the disease.
City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.
Since 2013, City of Hope researcher Saul Priceman, Ph.D., and his team have developed one of most comprehensive CAR T programs in the nation.
By moving all of the clinical research services and staff to one place, we are enabling many of our patients to complete all of their clinical trial appointments in a single visit at a single location. The Briskin Center includes infusion areas, nursing stations, exam and procedure rooms, onsite pharmacy and lab services, a dedicated registration site and outdoor seating for patients and their families.
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
These three City of Hope physicians have dramatically different backgrounds, but they share a devotion to helping people and saving lives and now they share in the generosity of longtime City of Hope philanthropists Norman and Melinda Payson. Vijay Trisal, M.D., Jeffrey Weitzel, M.D., and John Chan, M.D., were recent invested through gifts made from the Payson family.